Lucid Collecting Medicare Payments for EsoGuard as PAVmed Advances Veris Toward FDA Submission
PAVmed's preliminary third-quarter update shows its esophageal precancer test now earning Medicare reimbursement, while a first Veris Health device filing is lined up for early 2027.
PAVmed's most significant commercial news in its preliminary third-quarter 2026 update, issued on 13 November, is that Medicare has been paying for Lucid Diagnostics' EsoGuard test since October. EsoGuard is a DNA-based test for esophageal precancer.
Claims go to Novitas, the Medicare Administrative Contractor handling them, and are reimbursed at the existing rate on the Medicare clinical laboratory fee schedule. The update, as summarised to us, does not say how many claims have been paid, what they are worth or how quickly payment is arriving, so the revenue effect cannot yet be gauged.
On the device side, Veris Health has locked the design of its implantable monitor and begun a 90-day animal study run under Good Laboratory Practice standards. The company is aiming to file with the US Food and Drug Administration in early 2027. By way of context, the 510(k) route requires a manufacturer to show that its device is substantially equivalent to one already legally on the market.
PAVmed added that two other portfolio companies, PortIO and Octeris, have started engaging with the FDA. Neither the subject nor the stage of those discussions was specified, and no timelines were given.
Why it matters
- Medicare payment for EsoGuard is flowing through a single contractor, Novitas, at an existing fee-schedule rate rather than a newly negotiated one; volumes remain undisclosed.
- Veris Health's filing depends on the 90-day animal study, so the early-2027 target is tied to that study's completion.
- The design was frozen before the animal study began, which bears on the design-control record that will accompany the eventual 510(k).
- PortIO and Octeris are at an early point with the FDA, with no stated scope or schedule.
Company's press release (SEC filing): PAVmed Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
Medicare begins paying $1,938.01 per EsoGuard test as Lucid reports record October volume
